TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT03715933: Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Sponsor: Inhibrx Biosciences, Inc · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 411 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT03715933 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03715933 Rescue Dossier →